Sotera Health Company
SHCHealthcareNASDAQDiagnostics & Research · Last scanned Jun 3, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Sotera Health Company focuses on Diagnostics & Research services and products. Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. At a $4.28B market cap, Sotera Health Company ranks as a mid-cap company within healthcare. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs.
Market Cap
$4.28B
Beta
1.82
P/E (TTM)
36.63
P/E (Fwd)
14.17
EPS (TTM)
$0.41
EPS (Fwd)
$1.06
ROE
22.7%
ROA
8.5%
Cash
$314.4M
Total Debt
$2.27B
Free CF
$144.8M
52W Change
21.5%
Annual Financials
Cash vs Debt
On the balance sheet, SHC has $314.4M in cash with $2.27B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $144.8M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 22.7% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $1.00B to $1.16B.
Sotera Health Company's elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. No single metric tells the full story. Reviewing SHC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.